{"favorite_id": 3008, "calc_type": "", "dosing": false, "full_title_en": "IMDC (International Metastatic RCC Database Consortium) Risk Model for Metastatic Renal Cell Carcinoma", "short_title_en": "IMDC Model for mRCC", "medium_description_en": "Predicts survival in patients with metastatic renal cell carcinoma treated with systemic therapy (also known as Heng criteria).", "short_description_en": "Metastatic RCC survival.", "before_use": "", "instructions_en": "<p><span id=\"docs-internal-guid-bee24971-7fff-5e90-e787-ed8dcbb3db17\"></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Use baseline factors at the start date of the current line of systemic therapy, except for the &ldquo;time of diagnosis to systemic therapy&rdquo; criterion, which is always relative to first-line therapy.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Use limits of normal set by the laboratory performing the tests (for hemoglobin concentration, absolute neutrophil count, platelet count, corrected calcium concentration).</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Always <calculator id=\"31\">correct calcium concentration</calculator> for low albumin before scoring.</p>\n</li>\n</ul>", "purpose_en": ["Prognosis"], "disease_en": ["Chemotherapy", "Renal Cell Carcinoma"], "specialty_en": ["Hematology and Oncology", "Hospitalist Medicine", "Internal Medicine", "Nephrology", "Urology"], "chief_complaint_en": ["Flank Pain", "Hematuria"], "system_en": ["Oncologic", "Renal", "Urinary"], "search_abbreviation_en": ["heng", "vegf", "OS", "survival", "mets", "metastasis", "RCC", "heng score"], "slug": "imdc-international-metastatic-rcc-database-consortium-risk-model-metastatic-renal-cell-carcinoma", "seo": {"meta_description_en": "The IMDC (International Metastatic RCC Database Consortium) Risk Score for RCC predicts survival patients in metastatic renal cell carcinoma treated with systemic therapy.", "keywords_en": "heng, heng score, rcc score, motzer score, heng motzer score, rcc prognosis, heng cancer score, heng cancer prognosis, heng rcc score, renal cell carcinoma score, heng kidney cancer, kidney cancer score"}, "content": {"how_to_use": {"use_case_en": "<p><span id=\"docs-internal-guid-ded45bae-7fff-0e9e-218d-b9f3638bfb0a\">Patients with metastatic renal cell carcinoma.</p>", "pearls_pitfalls_en": "<p><span id=\"docs-internal-guid-82761a15-7fff-374b-6255-e827047b3dae\"></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Validated in the following settings:</p>\n</li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Patients with clear cell and non-clear cell metastatic renal cell carcinoma.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Patients undergoing targeted therapies and immune checkpoint inhibitor therapy.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Multiple care settings: clinical trial patients, patients receiving standard of care therapy at community and academic centers, and across multiple countries.</p>\n</li>\n</ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Can assist in the choice of systemic therapy.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Easy to use, uses readily available clinical and laboratory variables, and compares favorably to other similar prognosis prediction models.</p>\n</li>\n</ul>", "why_use_en": "<p>Assists clinicians in discussions about prognosis and in deciding the appropriate systemic therapy for patients with metastatic renal cell carcinoma.<br /><span id=\"docs-internal-guid-ed4972a1-7fff-6cef-e2f5-7c179fcb5c95\"></p>"}, "next_steps": {"advice_en": "", "management_en": "<p dir=\"ltr\">According to <a href=\"https://www.nccn.org/professionals/physician_gls/default.aspx\" target=\"_blank\">NCCN guidelines (v3.2019)</a>, choice of first-line systemic therapy for metastatic renal cell carcinoma based on risk group is:</p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Intermediate or poor risk</strong>: ipilimumab plus nivolumab (Phase III trial evidence) or cabozantinib (Phase II trial evidence).&nbsp;</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Favorable risk</strong>: PAZOPanib or SUNItinib.</p>\n</li>\n</ul>\n<div>\n<div>\n<div data-content=\"next-steps\">\n<div>\n<div>\n<p>Refer to&nbsp;<guideline id=\"10121\">AUA guidelines</guideline>&nbsp;for further details on management of renal cancer.</p>\n</div>\n</div>\n</div>\n</div>\n</div>", "critical_actions_en": "<p><span id=\"docs-internal-guid-db81bd2f-7fff-0a53-be2f-bb1558f63b2a\">Can only be applied to patients with metastatic renal cell carcinoma that receive systemic therapy.</p>"}, "about": {"formula_en": "<p>Addition of the selected points:</p>\n<table width=\"324\" height=\"132\">\n<tbody>\n<tr>\n<td>\n<p><strong>Variable</strong></p>\n</td>\n<td><strong>Points</strong></td>\n</tr>\n<tr>\n<td>\n<p>&lt;1&nbsp;year from time of diagnosis to systemic therapy</p>\n</td>\n<td>1</td>\n</tr>\n<tr>\n<td>\n<p><calculator id=\"3168\">Karnofsky performance status</calculator> &lt;80%</p>\n</td>\n<td>1</td>\n</tr>\n<tr>\n<td>\n<p>Hemoglobin &lt; lower limit of normal (usually ~120 g/L or 12 g/dL)</p>\n</td>\n<td>1</td>\n</tr>\n<tr>\n<td>\n<p><calculator id=\"31\">Corrected calcium</calculator> &gt; upper limit of normal (usually ~8.5-10.2 mg/dL)</p>\n</td>\n<td>1</td>\n</tr>\n<tr>\n<td>\n<p>Neutrophils &gt; upper limit of normal (usually ~2.0-7.0&times;10\u2079/L)</p>\n</td>\n<td>1</td>\n</tr>\n<tr>\n<td>\n<p>Platelets &gt; upper limit of normal (usually ~150,000-400,000 cells/&micro;L)</p>\n</td>\n<td>1</td>\n</tr>\n</tbody>\n</table>", "more_info_en": "<p>Interpretation:</p>\n<div class=\"table-responsive\">\n<table class=\"table table-bordered table-hover\">\n<tbody>\n<tr>\n<th>\n<p>IMDC Risk Score</p>\n</th>\n<th>Risk group</th>\n<th>Median survival</th>\n</tr>\n<tr>\n<td>\n<p>0</p>\n</td>\n<td>Favorable</td>\n<td>43.2 months</td>\n</tr>\n<tr>\n<td>\n<p>1-2</p>\n</td>\n<td>Intermediate</td>\n<td>22.5 months</td>\n</tr>\n<tr>\n<td>\n<p>&ge;3</p>\n</td>\n<td>Poor</td>\n<td>7.8 months</td>\n</tr>\n</tbody>\n</table>\n<p>From <a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144042/\" target=\"_blank\">Heng 2013</a>.</p>\n</div>", "evidence_based_medicine_en": "<p dir=\"ltr\">The International Metastatic RCC Database Consortium (IMDC) risk model was initially derived from a 2009 study of 645 patients with metastatic renal cell carcinoma treated with first-line targeted therapy in 3 US and 4 Canadian centers (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/19826129\" target=\"_blank\">Heng 2009</a>). The model showed a concordance index (C-index) of 0.73 and patients classified into the different risk groups had significantly different overall survival.</p>\n<p dir=\"ltr\">The model was subsequently externally validated (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144042/\" target=\"_blank\">Heng 2013</a>) in 849 consecutive patients with metastatic renal cell carcinoma from 13 international cancer centres and was shown to compare favorably to 4 other risk models used in this setting: Memorial Sloan Kettering Cancer Center (MSKCC) model, Cleveland Clinic Foundation (CCF) model, French model, and International Kidney Cancer Working Group (IKCWG) model.</p>\n<p dir=\"ltr\">The model has also been validated in patients with non-clear cell renal cell carcinoma (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/23696129\" target=\"_blank\">Kroeger 2013</a>), subsequent lines of therapy (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/25681967\" target=\"_blank\">Ko 2015</a>, <a href=\"https://www.europeanurology.com/article/S0302-2838(16)30258-5/fulltext\" target=\"_blank\">Wells 2017</a>), and patients treated by immune checkpoint inhibitors (<a href=\"http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.6_suppl.492\" target=\"_blank\">Yip 2017</a>).</p>\n<p><span id=\"docs-internal-guid-07f11c61-7fff-3a28-061a-cf8ee62e93c8\">Specific IMDC risk groups have also been shown to have better outcomes with certain systemic therapies. In particular, the IMDC intermediate and poor risk groups should be preferentially treated with first line nivolumab + ipilimumab or cabozantinib therapy (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29562145\" target=\"_blank\">Motzer 2018</a>, <a href=\"http://ascopubs.org/doi/full/10.1200/JCO.2016.70.7398\" target=\"_blank\">Choueiri 2017</a>, <a href=\"https://www.nccn.org/professionals/physician_gls/default.aspx\" target=\"_blank\">NCCN guidelines v3.2019</a>). Thus, IMDC risk groups have also become a tool for the selection of systemic therapy for first line clear cell metastatic renal cell carcinoma patients.</p>", "references_list": {"Original/Primary Reference": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/19826129", "text": "Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor\u2013Targeted Agents: Results From a Large, Multicenter Study. JCO Dec 1, 2009:5794-5799; published online on October 13, 2009."}], "Other References": [{"href": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.6_suppl.492", "text": "Yip S, Wells C, Moreira RB, et al. Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC. JCO (Abstract)."}, {"href": "http://ascopubs.org/doi/full/10.1200/JCO.2016.70.7398", "text": "Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib Versus SUNItinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017;35(6):591-597."}, {"href": "https://www.europeanurology.com/article/S0302-2838(16)30258-5/fulltext", "text": "Wells JC, Stukalin I, Norton C, et al. Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2017;71(2):204-209."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/29562145", "text": "Motzer RJ, Tannir NM, Mcdermott DF, et al. Nivolumab plus Ipilimumab versus SUNItinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277-1290."}], "Validation": [{"href": "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144042/", "text": "Heng DY, Xie W, Regan MM et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2),141-148."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/23696129", "text": "Kroeger N, Xie W, Lee JL, et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer. 2013;119(16):2999-3006."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/25681967", "text": "Ko JJ, Xie W, Kroeger N, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 2015;16(3):293-300."}], "Clinical Practice Guidelines": [], "Manufacturer Website": [], "Outcomes": []}}, "contributor": {"expert_name": [{"description": "<p>Ziad Bakouny, MD, MSc, is a postdoctoral genitourinary oncology research fellow at the Dana-Farber Cancer Institute/Harvard Cancer Center. Dr. Bakouny received his medical degree from the University of Saint Joseph in Beirut, Lebanon, during which time he concurrently obtained a master\u2019s in biomechanics and medical imaging. He has published more than 30 peer-reviewed papers, presented 70 abstracts at international scientific conferences, and received various awards for his research, including a Conquer Cancer Foundation merit award at the American Society of Clinical Oncology and Society for Immunotherapy of Cancer\u2019s clinical immuno-oncology symposium. His areas of interest include genitourinary oncology, biomarker research, and bioinformatics.</p>", "firstName": "Ziad", "img": "https://cdn-web-img.mdcalc.com/people/ziad-bakouny.jpg", "lastName": "Bakouny", "name": "Ziad Bakouny, MD, MSc", "target": "ziad-bakouny", "signedCOI": true, "hasDisclosure": []}]}, "creator": [{"name": "Dr. Daniel Heng", "qa_en": "", "approved": false, "creator_info": {"about_en": "<p>Daniel Heng, MD, MPH, is a staff medical oncologist at the Tom Baker Cancer Center in Calgary, Alberta, and a clinical professor of medicine at the University of Calgary. He holds a masters of public health from Harvard University and has a keen interest in outcomes, prognostic factors, and clinical trials research in kidney, bladder, prostate and testicular cancers.  He is the chair of the Southern Alberta Genitourinary Tumor Group.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-daniel-heng.jpeg", "pubmedLink": "http://www.ncbi.nlm.nih.gov/pubmed/?term=Heng%20DY%5Bauth%5D"}}, {"name": "Dr. Toni Choueiri", "qa_en": "", "approved": false, "creator_info": {"about_en": "Toni Choueiri, MD, is a medical oncologist and the director of the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute/Brigham and Women\u2019s Hospital in Boston, Massachusetts. He is also co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center and the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School. Dr. Choueiri's research interests include novel therapies and biomarkers in genitourinary malignancies.", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-toni-choueiri.jpg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Choueiri+TK%5BAuthor%5D"}}, {"name": "Dr. Wanling Xie", "qa_en": "", "approved": false, "creator_info": {"about_en": "Wanling Xie, PhD, is a biostatistician at the Dana-Farber Cancer Institute in Boston, Massachusetts. She has published and co-published dozens of peer-reviewed studies. Dr. Xie's research is mainly focused on genitourinary cancers, particularly metastatic renal cell carcinoma and prostate cancer.", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-wanling-xie.jpg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=wanling+xie%5Bau%5D"}}], "reviewer": {"expert_name": []}, "related_resources": {"mdcalc_rating": [], "guidelines": [{"id": 28, "order": 0, "society": "American Urological Association", "link": "https://www.mdcalc.com/guidelines/other/renal-mass-localized-renal-cancer", "text": "Renal Mass and Localized Renal Cancer", "description": "Guideline from AUA", "CalculatorId": 3008, "createdAt": "2019-07-02T20:19:02.411Z", "updatedAt": "2019-11-11T14:41:02.477Z"}], "teaching": [], "videos": [], "interests": [{"id": 11, "order": 0, "link": "https://www.mdcalc.com/rcc-renal-cell-carcinoma-practice-pearls", "text": "Practice Pearls: Renal Cell Carcinoma", "description": "", "CalculatorId": 3008, "createdAt": "2019-07-02T20:19:02.414Z", "updatedAt": "2019-07-02T20:19:02.414Z"}], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "toggle", "label_en": "<1 year from time of diagnosis to systemic therapy", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "dx"}, {"type": "toggle", "label_en": "<calculator id = \"3168\">Karnofsky Performance Status</calculator> <80%", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "perf"}, {"type": "toggle", "label_en": "Hemoglobin < lower limit of normal", "default": 0, "conditionality": "", "show_points": true, "tips_en": "Usually ~120 g/L or 12 g/dL", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "hgb"}, {"type": "toggle", "label_en": "<calculator id=\"31\">Corrected calcium</calculator> > upper limit of normal", "default": 0, "conditionality": "", "show_points": true, "tips_en": "Usually ~8.5-10.2 mg/dL", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "ca"}, {"type": "toggle", "label_en": "Neutrophils > upper limit of normal", "default": 0, "conditionality": "", "show_points": true, "tips_en": "Usually ~2.0-7.0\u00d710\u2079/L", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "neut"}, {"type": "toggle", "label_en": "Platelets > upper limit of normal", "default": 0, "conditionality": "", "show_points": true, "tips_en": "Usually ~150,000-400,000 cells/\u00b5L", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "plt"}], "md5": "", "cmeVersion": "3008.1", "related_calcs": [{"calcId": 3011, "short_title_en": "TNM RCC Staging", "slug": "tnm-staging-renal-cell-carcinoma"}, {"calcId": 10122, "short_title_en": "TNM RCC Staging (8th Ed.)", "slug": "tnm-staging-renal-cell-carcinoma-rcc-8th-edition"}, {"calcId": 3009, "short_title_en": "UISS for RCC", "slug": "ucla-integrated-staging-system-uiss-renal-cell-carcinoma-rcc"}]}